Treatment of coccidioidomycosis with SCH 39304

J. S. Hostetler, A. Catanzaro, D. A. Stevens, J. R. Graybill, P. K. Sharkey, R. A. Larsen, R. M. Tucker, A. D. Al-Haidary, M. G. Rinaldi, G. A. Cloud, John N Galgiani

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A new oral triazole antifungal, SCH 39304, was administered to 54 patients with progressive infections due to Coccidioides immitis from six collaborating centers. Patients were grouped according to site of infection including chronic pulmonary (25), bone/joint (17) and skin/soft tissue (12). The median age was 40 years; 83% were male, 52% white, 13% HIV-infected and 35% had failed previous therapy. The majority of patients were treated with either 100 mg or 200 mg day-1. One patient on renal dialysis received 300 mg day-1. Baseline abnormalities were reassessed for evidence of efficacy every 4 months and expressed in a standardized scoring system. Cumulative overall response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively. Twelve month response rates by disease were 77% (pulmonary), 62% (skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy although seven of these were still on treatment when the study was discontinued. Two failed due to toxicity. Possible symptoms or signs of toxicity occurred in 24 (44%) patients and were generally mild. SCH 39304 is an effective and well tolerated therapy for progressive forms of coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)105-114
Number of pages10
JournalJournal of Medical and Veterinary Mycology
Volume32
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Coccidioidomycosis
Therapeutics
Joints
Coccidioides
Bone and Bones
Lung
Skin
Triazoles
Infection
Signs and Symptoms
Renal Dialysis
HIV

ASJC Scopus subject areas

  • Microbiology

Cite this

Hostetler, J. S., Catanzaro, A., Stevens, D. A., Graybill, J. R., Sharkey, P. K., Larsen, R. A., ... Galgiani, J. N. (1994). Treatment of coccidioidomycosis with SCH 39304. Journal of Medical and Veterinary Mycology, 32(2), 105-114.

Treatment of coccidioidomycosis with SCH 39304. / Hostetler, J. S.; Catanzaro, A.; Stevens, D. A.; Graybill, J. R.; Sharkey, P. K.; Larsen, R. A.; Tucker, R. M.; Al-Haidary, A. D.; Rinaldi, M. G.; Cloud, G. A.; Galgiani, John N.

In: Journal of Medical and Veterinary Mycology, Vol. 32, No. 2, 1994, p. 105-114.

Research output: Contribution to journalArticle

Hostetler, JS, Catanzaro, A, Stevens, DA, Graybill, JR, Sharkey, PK, Larsen, RA, Tucker, RM, Al-Haidary, AD, Rinaldi, MG, Cloud, GA & Galgiani, JN 1994, 'Treatment of coccidioidomycosis with SCH 39304', Journal of Medical and Veterinary Mycology, vol. 32, no. 2, pp. 105-114.
Hostetler JS, Catanzaro A, Stevens DA, Graybill JR, Sharkey PK, Larsen RA et al. Treatment of coccidioidomycosis with SCH 39304. Journal of Medical and Veterinary Mycology. 1994;32(2):105-114.
Hostetler, J. S. ; Catanzaro, A. ; Stevens, D. A. ; Graybill, J. R. ; Sharkey, P. K. ; Larsen, R. A. ; Tucker, R. M. ; Al-Haidary, A. D. ; Rinaldi, M. G. ; Cloud, G. A. ; Galgiani, John N. / Treatment of coccidioidomycosis with SCH 39304. In: Journal of Medical and Veterinary Mycology. 1994 ; Vol. 32, No. 2. pp. 105-114.
@article{7696268d4e9e4d139a79c6ad74197e99,
title = "Treatment of coccidioidomycosis with SCH 39304",
abstract = "A new oral triazole antifungal, SCH 39304, was administered to 54 patients with progressive infections due to Coccidioides immitis from six collaborating centers. Patients were grouped according to site of infection including chronic pulmonary (25), bone/joint (17) and skin/soft tissue (12). The median age was 40 years; 83{\%} were male, 52{\%} white, 13{\%} HIV-infected and 35{\%} had failed previous therapy. The majority of patients were treated with either 100 mg or 200 mg day-1. One patient on renal dialysis received 300 mg day-1. Baseline abnormalities were reassessed for evidence of efficacy every 4 months and expressed in a standardized scoring system. Cumulative overall response rates at 4, 8 and 12 months were 7{\%}, 36{\%} and 66{\%} respectively. Twelve month response rates by disease were 77{\%} (pulmonary), 62{\%} (skin/soft tissue) and 31{\%} (bone/joint). Fifteen patients failed therapy although seven of these were still on treatment when the study was discontinued. Two failed due to toxicity. Possible symptoms or signs of toxicity occurred in 24 (44{\%}) patients and were generally mild. SCH 39304 is an effective and well tolerated therapy for progressive forms of coccidioidomycosis.",
author = "Hostetler, {J. S.} and A. Catanzaro and Stevens, {D. A.} and Graybill, {J. R.} and Sharkey, {P. K.} and Larsen, {R. A.} and Tucker, {R. M.} and Al-Haidary, {A. D.} and Rinaldi, {M. G.} and Cloud, {G. A.} and Galgiani, {John N}",
year = "1994",
language = "English (US)",
volume = "32",
pages = "105--114",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Treatment of coccidioidomycosis with SCH 39304

AU - Hostetler, J. S.

AU - Catanzaro, A.

AU - Stevens, D. A.

AU - Graybill, J. R.

AU - Sharkey, P. K.

AU - Larsen, R. A.

AU - Tucker, R. M.

AU - Al-Haidary, A. D.

AU - Rinaldi, M. G.

AU - Cloud, G. A.

AU - Galgiani, John N

PY - 1994

Y1 - 1994

N2 - A new oral triazole antifungal, SCH 39304, was administered to 54 patients with progressive infections due to Coccidioides immitis from six collaborating centers. Patients were grouped according to site of infection including chronic pulmonary (25), bone/joint (17) and skin/soft tissue (12). The median age was 40 years; 83% were male, 52% white, 13% HIV-infected and 35% had failed previous therapy. The majority of patients were treated with either 100 mg or 200 mg day-1. One patient on renal dialysis received 300 mg day-1. Baseline abnormalities were reassessed for evidence of efficacy every 4 months and expressed in a standardized scoring system. Cumulative overall response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively. Twelve month response rates by disease were 77% (pulmonary), 62% (skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy although seven of these were still on treatment when the study was discontinued. Two failed due to toxicity. Possible symptoms or signs of toxicity occurred in 24 (44%) patients and were generally mild. SCH 39304 is an effective and well tolerated therapy for progressive forms of coccidioidomycosis.

AB - A new oral triazole antifungal, SCH 39304, was administered to 54 patients with progressive infections due to Coccidioides immitis from six collaborating centers. Patients were grouped according to site of infection including chronic pulmonary (25), bone/joint (17) and skin/soft tissue (12). The median age was 40 years; 83% were male, 52% white, 13% HIV-infected and 35% had failed previous therapy. The majority of patients were treated with either 100 mg or 200 mg day-1. One patient on renal dialysis received 300 mg day-1. Baseline abnormalities were reassessed for evidence of efficacy every 4 months and expressed in a standardized scoring system. Cumulative overall response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively. Twelve month response rates by disease were 77% (pulmonary), 62% (skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy although seven of these were still on treatment when the study was discontinued. Two failed due to toxicity. Possible symptoms or signs of toxicity occurred in 24 (44%) patients and were generally mild. SCH 39304 is an effective and well tolerated therapy for progressive forms of coccidioidomycosis.

UR - http://www.scopus.com/inward/record.url?scp=0028360618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028360618&partnerID=8YFLogxK

M3 - Article

C2 - 8064541

AN - SCOPUS:0028360618

VL - 32

SP - 105

EP - 114

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 2

ER -